Raytheon SharpSight Order Bolsters Backlog, but Execution Hurdles Remain

What happened

Raytheon, an RTX business, secured its largest single order for SharpSight radars from Blue Raven, expanding global access to the multi-domain surveillance system. However, the DeepValue report highlights that Raytheon's defense backlog sequentially declined in Q1 2026 despite robust bookings, underscoring that delivery conversion—not just order intake—remains the critical variable. While the order adds to headline momentum, it does not alter the fundamental thesis that RTX must demonstrate improved throughput at both Raytheon and Pratt & Whitney in the coming quarters. The stock's premium valuation leaves it vulnerable to any guidance reset or extended GTF disruption, meaning near-term sentiment may improve, but the wait-for-evidence stance is unchanged. Investors should treat this as a positive data point within a larger execution narrative, not a call to re-rate.

Implication

The SharpSight order is a modest pipeline positive, but the thesis hinges on Raytheon's delivery ramp and Pratt's AOG trajectory. Until backlog grows sequentially and GTF remediation shows clear cash-flow improvement, the risk/reward is balanced at current multiples. Maintain WAIT until operational proof emerges in the next 2-3 quarters.

Thesis delta

The SharpSight order modestly strengthens Raytheon's backlog optics but does not shift the core thesis: RTX needs visible delivery conversion and Pratt remediation progress to justify its premium valuation. The watch-and-wait stance remains intact, with no change to the base-case $185 target or the $160 attractive entry.